Elsa Miekoutima

Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Journal of Clinical Oncology · 2021 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia

Nabih Maslah, Norman Salomao, Louis Drevon et al. · Haematologica · 2019 · 139 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Blood · 2019 · 65 citations

Medicine, Oncology, Pharmacotherapy +16

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Jérémie Zerbit, Marion Detroit, Antoine Meyer et al. · Viruses · 2022 · 30 citations · Full text

Medicine, Hematology, Immunology +17

Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France

Mariem Raho-Moussa, Marguerite Guiguet, Céline Michaud et al. · PLoS ONE · 2019 · 18 citations · Full text

Public Health, Health Sciences, Population Health Sciences +15